Insuficien a cardiacă avansată (AHF) este stadiul insuficien ei cardiace (IC) refractară la tratamentul medical maximal, dispozitive cardiace (CRT -resincronizare cardiacă, ICDdefibrilator implantabil) și tratament chirurgical. AHF a devenit actuală prin experien a și rezultatele favorabile ale tratamentului prin suport circulator mecanic (MCS) și transplant cardiac (CT). Articolul trece în revistă criteriile de definire ale AHF (2018 ESC statement), istoria naturală și prognosticul în afara formelor de tratament avansat. Evaluarea factorilor de risc și de prognostic este necesară înainte de decizia tratament avansat: factorii clinici (severitatea IC și reducerea capacită ii func ionale cardiorespiratorii), func ia VD, markerii biologici și elementele de disfunc ie de organ, precum și reducerea toleran ei la medica ia conven ională. În încheiere, sunt prezentate principiile de tratament și rezultatele prin suport circulator mecanic și transplant cardiac. Cuvinte cheie: insuficien a cardiacă avansată, suport circulator mecanic, transplant cardiac.
The term "advanced heart failure" (AHF), generically used since 2007, defined the stage of heart failure (HF) in which maximal medical treatment, the use of cardiac devices and surgical procedures, where deemed insufficient for controlling its evolution . The term AHF is equal to the (1) terms of "end stage heart failure", class D or class IV NYHA HF.
Defining the criteria for AHF is necessary among cardiologists, given the recent treatment advances for the so-called Heart Association (2013) and the Heart (2) Failure Society of America (2016) , ( 3 ) Given the new data regarding AHF, discussed in the statements above, this paper will present the prevalence, the accepted criteria for defining AHF, the main negative predictors which guide patients towards a d v a n c e d t h e r a p y a n d t h e g e n e r a l guidelines for the management of AHF. It must be stressed that terms like acute and chronic HF, class I-IV NYHA HF, acutely decompensated chronic HF, HF with preserved or increased ejection fraction, worsening HF and refractory HF maintain their current accepted definitions. Patients from these types and classes of HF are selected for potential advanced therapies (mechanical circulatory support, cardiac t r a n s p l a n t a t i o n ) o r e n d -o f-l i f e c a re programmes.
The prevalence of AHF is estimated based on its accepted definition. Data from the ADHERE Registry (Acute Decompensated Heart Failure National Registry) showed that about 5% of end-stage patients have signs and symptoms refractory to medical therapy and can be classified as AHF . Other data (3) estimate the prevalence of AHF as between 6% and 25%, depending on the used definition and the studied population . In (5) general, the prevalence estimation varies b e t w e e n r e g i s t r i e s , t r i a l s a n d t h e physiopathologic type of HF (with reduced or preserved HF). Patients with stage D HF are considered having AHF, as well as some patients in class NYHA III and IV that are refractory to optimal medical therapy. 
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